Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-07 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
11/07/25	2.660 $	+3.10%	366,420
10/07/25	2.580 $	+1.57%	33,275
09/07/25	2.540 $	+2.42%	61,971
08/07/25	2.480 $	+7.83%	32,403
07/07/25	2.300 $	-3.77%	41,221

Delayed Quote Nasdaq, July 12, 2025 at 12:00 am

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.660USD

Average target price

13.25USD

Spread / Average Target

+398.12%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 00:00:00 12/07/2025 +04			5-day change	1st Jan Change
2.660 ^USD	+3.10%		+11.30%	-37.07%

07-11	European Equities Traded in the US as American Depositary Receipts Drop Sharply in Friday Trading	MT
07-11	Evaxion Shares Rise Premarket After Company Secures Debt-to-Equity Deal With European Investment Bank	MT

Capitalization	16.8M 14.37M 13.38M 12.45M 23M 1.44B 25.56M 160M 61.31M 675M 63.02M 61.72M 2.48B	P/E ratio 2025 *	-1.22x	P/E ratio 2026 *	-2.17x
Enterprise value	16.8M 14.37M 13.38M 12.45M 23M 1.44B 25.56M 160M 61.31M 675M 63.02M 61.72M 2.48B	EV / Sales 2025 *	-	EV / Sales 2026 *	3.78x
Free-Float	74.75%	Yield 2025 *	-	Yield 2026 *	-

European Equities Traded in the US as American Depositary Receipts Drop Sharply in Friday Trading	07-11	MT
Evaxion Shares Rise Premarket After Company Secures Debt-to-Equity Deal With European Investment Bank	07-11	MT
European Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading	07-08	MT
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	07-07	MT
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading	07-03	MT
Evaxion A/S Announces CEO Changes	07-02	CI
Evaxion A/S Appoints Thomas Schmidt as Chief Financial Officer	07-02	CI
European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading	07-01	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 2.5% for Week	06-27	MT
Evaxion Expands R&D Pipeline with New Vaccine Program Targeting Group A Streptococcus	06-25	CI
Evaxion A/S, Q1 2025 Earnings Call, May 27, 2025	06-23
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading	06-23	MT
European Equities Traded in the US as American Depositary Receipts Retreat Friday	06-20	MT

Ladenburg Thalmann Upgrades Evaxion Biotech to Buy From Neutral, Price Target is $8	02/04/24	MT
HC Wainwright Initiates Evaxion Biotech With Buy Rating, Price Target is $14	12/02/24	MT
Ladenburg Thalmann Downgrades Evaxion Biotech to Neutral From Buy	21/12/23	MT
Lake Street Cuts Price Target on Evaxion Biotech to $7 From $18, Maintains Buy Rating	31/03/23	MT
Oppenheimer Adjusts Evaxion Biotech Price Target to $11 From $16, Maintains Outperform Rating	17/11/22	MT

Evaxion A/S Stock

Equities

EVAX

US29970R3030

Biotechnology & Medical Research

Valuation: Evaxion A/S

Chart: Evaxion A/S

Latest news: Evaxion A/S

Last Transcript: Evaxion A/S

Analysts' recommendations: Evaxion A/S

Press Releases: Evaxion A/S

News in other languages: Evaxion A/S

Quotes and Performance

Course Extremes

Managers and Directors: Evaxion A/S

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Evaxion finalizes agreement with EIB to convert debt into equity	07-11	AQ
Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio	07-01	AQ
Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus	06-25	AQ
Evaxion receives grant funding to design new polio vaccine	06-03	AQ
Evaxion A/S : Q1 Presentation	05-27	PU

Evaxion annonce un plan visant à mettre en œuvre la modification du ratio de ses ADS	09/01/24
Evaxion kündigt Plan zur Änderung des ADS-Verhältnisses an	09/01/24
Clôture du financement par placement privé pour Evaxion Biotech	23/12/23
Evaxion Biotech gibt Abschluss einer Privatplatzierung bekannt	23/12/23
Un financement par placement privé pour Evaxion Biotech	20/12/23

1 day	+3.10%
1 week	+11.30%
Current month	+8.57%
1 month	-7.96%
3 months	+97.04%
6 months	-40.89%
Current year	-37.07%

1 week	2.26	2.85
1 month	2.07	2.95
Current year	1.2	9.8
1 year	1.2	17.75
3 years	1.2	176
5 years	1.2	1,252
10 years	1.2	1,252

Manager	Title	Age	Since
Andreas Mattsson PRN	Corporate Officer/Principal	48	11/08/2008
Birgitte Rono CEO	Chief Executive Officer	48	01/07/2025
Thomas Schmidt DFI	Director of Finance/CFO	52	01/11/2024

Director	Title	Age	Since
Marianne Søgaard CHM	Chairman	57	25/11/2020
Roberto Prego Pineda BRD	Director/Board Member	55	01/01/2018
Lars Holtug BRD	Director/Board Member	67	25/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
EVAXION A/S	+3.10%	+11.30%	-83.38%	-97.68%	16.8M
LONZA GROUP AG	-0.95%	+0.68%	+8.34%	-0.88%	50.02B
BEONE MEDICINES LTD.	-1.22%	+1.96%	+66.31%	+41.40%	29.65B
CELLTRION, INC.	0.00%	+0.34%	+4.97%	+9.05%	28.69B
IQVIA HOLDINGS INC.	-1.65%	-0.88%	-25.81%	-25.11%	28.16B
EUROFINS SCIENTIFIC SE	-0.03%	-0.39%	+25.47%	-22.17%	12.7B
ICON PUBLIC LIMITED COMPANY	-1.02%	+0.28%	-54.96%	-29.86%	11.96B
ASCENDIS PHARMA A/S	-0.87%	+0.45%	+28.92%	+92.75%	10.59B
QIAGEN N.V.	-0.87%	-0.43%	+13.82%	-5.30%	10.42B
TEMPUS AI, INC.	-4.56%	-6.71%	+51.68%	-	9.85B
Average	-0.40%	+1.22%	+3.54%	-4.20%	19.21B
Weighted average by Cap.	-0.86%	+0.62%	+12.61%	+5.61%

	2025 *	2026 *
Net sales	-	4.44M 3.8M 3.54M 3.29M 6.08M 381M 6.76M 42.42M 16.22M 179M 16.67M 16.32M 655M
Net income	-10.62M -9.08M -8.46M -7.87M -14.53M -911M -16.15M -101M -38.75M -427M -39.82M -39M -1.56B	-12.48M -10.67M -9.94M -9.25M -17.09M -1.07B -18.99M -119M -45.55M -501M -46.82M -45.85M -1.84B
Net Debt	-	-